Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Serebruany
Victor L
VL
Heart Drug, Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA. heartdrug@aol.com
Alberts
Mark J
MJ
Hanley
Dan F
DF
D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D000077144:Clopidogrel; D004311:Double-Blind Method; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications* / Q000628:therapy; D010879:Piperazines / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D000068799:Prasugrel Hydrochloride; D011446:Prospective Studies; D055502:Secondary Prevention; D015607:Stents; D020521:Stroke / Q000150:complications* / Q000628:therapy; D013876:Thiophenes / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine